{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:48:35Z","timestamp":1791492515847,"version":"4.3.4"},"reference-count":80,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>To effectively combat emerging infections and prevent future pandemics, next generation vaccines must be developed quickly, manufactured rapidly, and most critically, administered easily. Next generation vaccines need innovative approaches that prevent infection, severe disease, and reduce community transmission of respiratory pathogens such as influenza and SARS-CoV-2. Here we review an oral vaccine tablet that can be manufactured and released in less than 16 weeks of antigen design and deployed without the need for cold chain. The oral Ad5 modular vaccine platform utilizes a non-replicating adenoviral vector (rAd5) containing a novel molecular TLR3 adjuvant that is delivered by tablet, not by needle. This enterically coated, room temperature-stable vaccine tablet elicits robust antigen-specific IgA in the gastrointestinal and respiratory tracts and upregulates mucosal homing adhesion molecules on circulating B and T cells. Several influenza antigens have been tested using this novel vaccine approach and demonstrated efficacy in both preclinical animal models and in phase I\/II clinical trials, including in a human challenge study. This oral rAd5 vaccine platform technology offers a promising new avenue for aiding in rapid pandemic preparedness and equitable worldwide vaccine distribution.<\/jats:p>","DOI":"10.3390\/vaccines10040593","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T22:48:45Z","timestamp":1649803725000},"page":"593","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Drop the Needle; A Temperature Stable Oral Tablet Vaccine Is Protective against Respiratory Viral Pathogens"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-8751","authenticated-orcid":false,"given":"Becca A.","family":"Flitter","sequence":"first","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly R.","family":"Braun","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean N.","family":"Tucker","sequence":"additional","affiliation":[{"name":"Vaxart, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"ref_1","unstructured":"Lowe, D. (2021, October 16). Cold Chain (and Colder Chain) Distribution. Science. Available online: https:\/\/blogs.sciencemag.org\/pipeline\/archives\/2020\/08\/31\/cold-chain-and-colder-chain-distribution."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e006852","DOI":"10.1136\/bmjgh-2021-006852","article-title":"Building the evidence base for global health policy: The need to strengthen institutional networks, geographical representation and global collaboration","volume":"6","author":"Jakab","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"ref_3","first-page":"e70","article-title":"Ensuring health equity during the COVID-19 pandemic: The role of public health infrastructure","volume":"44","author":"Benjamin","year":"2020","journal-title":"Rev. Panam. Salud P\u00fablica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11095-021-03008-w","article-title":"Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics","volume":"38","author":"Yu","year":"2021","journal-title":"Pharm. Res."},{"key":"ref_5","unstructured":"(2021, November 11). QuadrantSolutions. Available online: https:\/\/investors.vaxart.com\/static-files\/cbf26eda-2ffa-4cb2-b031-0cb9b02fedac."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"37295","DOI":"10.1038\/srep37295","article-title":"Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule","volume":"6","author":"Kim","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: A placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: A phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.chom.2021.10.009","article-title":"Human influenza virus challenge identifies cellular correlates of protection for oral vaccination","volume":"29","author":"McIlwain","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Langel, S.N., Johnson, S., Martinez, C.I., Tedjakusuma, S.N., Peinovich, N., Dora, E.G., Kuehal, P.J., Irshad, H., Barrett, E.G., and Werts, A. (2021). Oral and intranasal Ad5 SARS-CoV-2 vaccines decrease disease and viral transmission in a golden hamster model. bioRxiv.","DOI":"10.1101\/2021.10.03.462919"},{"key":"ref_11","unstructured":"WHO (2021, October 23). Pandemic Influenza Vaccine Manufacturing Process and Timeline. Available online: https:\/\/www.who.int\/news\/item\/06-08-2009-pandemic-influenza-vaccine-manufacturing-process-and-timeline."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021\u20132022 Influenza Season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm. Rep."},{"key":"ref_13","unstructured":"(2022, February 20). GISRS. Available online: https:\/\/www.who.int\/initiatives\/global-influenza-surveillance-and-response-system."},{"key":"ref_14","first-page":"583","article-title":"Influenza Activity\u2014United States, 2014\u20132015 Season and Composition of the 2015\u201316 Influenza Vaccine","volume":"64","author":"Appiah","year":"2015","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Harding, A.T., and Heaton, N.S. (2018). Efforts to Improve the Seasonal Influenza Vaccine. Vaccines, 6.","DOI":"10.3390\/vaccines6020019"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01031-17","DOI":"10.1128\/JVI.01031-17","article-title":"Complexities of Viral Mutation Rates","volume":"92","author":"Peck","year":"2018","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2020368118","DOI":"10.1073\/pnas.2020368118","article-title":"Vaccinology in the post-COVID-19 era","volume":"118","author":"Rappuoli","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","first-page":"509","article-title":"COVID-19 Healthcare Inequity: Lessons Learned from Annual Influenza Vaccination Rates to Mitigate COVID-19 Vaccine Disparities","volume":"94","author":"Bazan","year":"2021","journal-title":"Yale J. Biol. Med."},{"key":"ref_22","first-page":"102620","article-title":"Disparities in global COVID-19 vaccination rates & allocation of resources to countries in need","volume":"68","author":"McKenney","year":"2021","journal-title":"Ann. Med. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the Cold Reality of mRNA Vaccine Stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_24","unstructured":"Levin, D. (The New York Times, 2021). The U.S. Is Wasting Vaccine Doses, Even as Cases Rise and Other Countries Suffer Shortages, The New York Times."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111400","DOI":"10.1016\/j.rser.2021.111400","article-title":"COVID-19 pandemics Stage II\u2014Energy and environmental impacts of vaccination","volume":"150","author":"Klemes","year":"2021","journal-title":"Renew. Sustain. Energy Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"ref_31","first-page":"363","article-title":"Cross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell Subsets","volume":"6","author":"Planes","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3389\/fimmu.2018.02144","article-title":"Epithelial MHC Class II Expression and Its Role in Antigen Presentation in the Gastrointestinal and Respiratory Tracts","volume":"9","author":"Wosen","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","article-title":"Influence of protein fold stability on immunogenicity and its implications for vaccine design","volume":"16","author":"Scheiblhofer","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Weldon, W.C., Wang, B.Z., Martin, M.P., Koutsonanos, D.G., Skountzou, I., and Compans, R.W. (2010). Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012466"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"611337","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Stephenson, K.E., Keefer, M.C., Bunce, C.A., Frances, D., Abbink, P., Maxfield, L.F., Neubauer, G.H., Nkolola, J., Peter, L., and Lane, C. (2018). First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205139"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines\u2014Fortifying the frontiers","volume":"22","author":"Lavelle","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.2174\/138161207781039814","article-title":"The biology of oral tolerance and issues related to oral vaccine design","volume":"13","author":"Poonam","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1369\/0022155416656154","article-title":"The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer","volume":"64","author":"Huhta","year":"2016","journal-title":"J. Histochem. Cytochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1128\/IAI.68.12.7010-7017.2000","article-title":"Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease","volume":"68","author":"Cario","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e12225","DOI":"10.14814\/phy2.12225","article-title":"Pattern recognition receptors in the gut: Analysis of their expression along the intestinal tract and the crypt\/villus axis","volume":"3","author":"Gourbeyre","year":"2015","journal-title":"Physiol Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"498703","DOI":"10.3389\/fimmu.2020.498703","article-title":"Interferon alpha Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus","volume":"11","author":"Akita","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108211","DOI":"10.1016\/j.celrep.2020.108211","article-title":"Interferon-lambda Enhances the Differentiation of Naive B Cells into Plasmablasts via the mTORC1 Pathway","volume":"33","author":"Syedbasha","year":"2020","journal-title":"Cell Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41590-019-0408-z","article-title":"Interferon-lambda modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus","volume":"20","author":"Hemann","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1128\/JVI.79.5.2910-2919.2005","article-title":"Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection","volume":"79","author":"Ichinohe","year":"2005","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/mi.2017.48","article-title":"Toll-like receptor 3 in nasal CD103(+) dendritic cells is involved in immunoglobulin A production","volume":"11","author":"Takaki","year":"2018","journal-title":"Mucosal Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Muramatsu, M., Yoshida, R., Yokoyama, A., Miyamoto, H., Kajihara, M., Maruyama, J., Nao, N., Manzoor, R., and Takada, A. (2014). Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: Increased potential of IgA for heterosubtypic immunity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085582"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Saito, S., Sano, K., Suzuki, T., Ainai, A., Taga, Y., Ueno, T., Tabata, K., Saito, K., Wada, Y., and Ohara, Y. (2019). IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007427"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/mi.2007.6","article-title":"The immune geography of IgA induction and function","volume":"1","author":"Macpherson","year":"2008","journal-title":"Mucosal Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/eji.1830260427","article-title":"Distribution of alpha 4 beta 7 and alpha E beta 7 integrins on thymocytes, intestinal epithelial lymphocytes and peripheral lymphocytes","volume":"26","author":"Andrew","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1172\/JCI119286","article-title":"Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses","volume":"99","author":"Nordstrom","year":"1997","journal-title":"J. Clin. Invest."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1073\/pnas.1019378108","article-title":"Microbiota regulates immune defense against respiratory tract influenza A virus infection","volume":"108","author":"Ichinohe","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1128\/CVI.00552-12","article-title":"An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models","volume":"20","author":"Scallan","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.coi.2009.05.023","article-title":"Immunosenescence: What does it mean to health outcomes in older adults?","volume":"21","author":"McElhaney","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.vaccine.2009.01.136","article-title":"Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults","volume":"27","author":"McElhaney","year":"2009","journal-title":"Vaccine"},{"key":"ref_59","unstructured":"Tucker, S.N. (2021, November 19). Vaxart\u2019s Oral Vaccine Candidate for Prevention of COVID-19: Hold the Needes and the Ice. Available online: https:\/\/www.humanvaccinesproject.org\/event\/march-11th-speaker-sean-tucker\/."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nri3608","article-title":"Intestinal epithelial cells: Regulators of barrier function and immune homeostasis","volume":"14","author":"Peterson","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fimmu.2013.00185","article-title":"Multi-faceted functions of secretory IgA at mucosal surfaces","volume":"4","author":"Corthesy","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7883\/yoken.JJID.2005.195","article-title":"Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines","volume":"58","author":"Tamura","year":"2005","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1084\/jem.161.1.198","article-title":"Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG","volume":"161","author":"Taylor","year":"1985","journal-title":"J. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.1503885112","article-title":"Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus","volume":"112","author":"Suzuki","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1365-3083.2000.00790.x","article-title":"Role of J chain in secretory immunoglobulin formation","volume":"52","author":"Johansen","year":"2000","journal-title":"Scand. J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jviromet.2017.10.022","article-title":"Colocalization of intracellular specific IgA (icIgA) with influenza virus in patients' nasopharyngeal aspirate cells","volume":"252","author":"Kok","year":"2018","journal-title":"J. Virol. Methods"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"13463","DOI":"10.1073\/pnas.1410980111","article-title":"Translocalized IgA mediates neutralization and stimulates innate immunity inside infected cells","volume":"111","author":"Bidgood","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1073\/pnas.89.15.6901","article-title":"Intracellular neutralization of virus by immunoglobulin A antibodies","volume":"89","author":"Mazanec","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.1016\/j.vaccine.2012.09.018","article-title":"The role of nasal IgA in children vaccinated with live attenuated influenza vaccine","volume":"30","author":"Ambrose","year":"2012","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fmicb.2017.00900","article-title":"Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre","volume":"8","author":"Gould","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lambkin-Williams, R., Gelder, C., Broughton, R., Mallett, C.P., Gilbert, A.S., Mann, A., He, D., Oxford, J.S., and Burt, D. (2016). An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163089"},{"key":"ref_72","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J. Hyg."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Coudeville, L., Bailleux, F., Riche, B., Megas, F., Andre, P., and Ecochard, R. (2010). Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: Development and application of a bayesian random-effects model. BMC Med. Res. Methodol., 10.","DOI":"10.1186\/1471-2288-10-18"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/infdis\/jir661","article-title":"Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection","volume":"204","author":"Ohmit","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15279","DOI":"10.1038\/srep15279","article-title":"H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps","volume":"5","author":"Xie","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/21645515.2017.1377376","article-title":"Immune responses after live attenuated influenza vaccination","volume":"14","author":"Mohn","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.vaccine.2016.11.082","article-title":"Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection","volume":"35","author":"Nieuwkoop","year":"2017","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/14760584.2018.1516553","article-title":"Effector mechanisms of influenza-specific antibodies: Neutralization and beyond","volume":"17","author":"Sicca","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1128\/JVI.00979-13","article-title":"Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs","volume":"87","author":"Seibert","year":"2013","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.vaccine.2013.01.023","article-title":"Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-gamma T cell responses in humans","volume":"31","author":"Peters","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/4\/593\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:52:28Z","timestamp":1760136748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/4\/593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["vaccines10040593"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10040593","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}